Skip to main content

Schnitzler Syndrome

  • Chapter
  • First Online:
Textbook of Autoinflammation

Abstract

Schnitzler syndrome (SchS) is a late-onset autoinflammatory disease characterized by the association of a chronic urticarial rash and monoclonal gammopathy with signs and symptoms of systemic inflammation. Clinical efficacy of IL-1ß blocking drugs revealed the key role of IL-1ß in the pathophysiology of SchS. This was corroborated by in vitro and genetic studies. Anti-IL-1ß treatment abrogates the systemic inflammation, but leaves the monoclonal gammopathy unaffected. The role of the monoclonal gammopathy (cause or consequence) is the major question that remains to be resolved.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 169.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Abbreviations

CAPS:

Cryopyrin-associated periodic syndrome

CNO:

Chronic non-bacterial osteomyelitis

CRP:

C-reactive protein

CSU:

Chronic spontaneous urticaria

ESR:

Erythrocyte sedimentation rate

Ig:

Immunoglobulin

IL-1:

Interleukin-1

MGUS:

Monoclonal gammopathy of unknown significance

MRP:

Myeloid-related protein

NUD:

Neutrophilic urticarial dermatosis

PBMCs:

Peripheral blood mononuclear cells

SchS:

Schnitzler syndrome

TLR:

Toll-like receptor

References

  1. Schnitzler L. Lésions urticariennes chroniques permanentes (erytheme pétaloide?) Journee Dermatologique d’Angers. 1972:Cas cliniques. No. 46B.

    Google Scholar 

  2. Schnitzler L, Hurez D, Verret JL. Chronic urticaria—osteo-condensation—macroglobulinemia. Principal case. Study of 20 cases. Ann Dermatol Venereol. 1989;116:547–50.

    CAS  PubMed  Google Scholar 

  3. Pizzirani C, Falzoni S, Govoni M, et al. Dysfunctional inflammasome in Schnitzler’s syndrome. Rheumatology. 2009;48:1304–8.

    Article  CAS  Google Scholar 

  4. Ryan JG, de Koning HD, Beck LA, Booty MG, Kastner DL, Simon A. IL-1 blockade in Schnitzler syndrome: ex vivo findings correlate with clinical remission. J Allergy Clin Immunol. 2008;121:260–2.

    Article  CAS  Google Scholar 

  5. Simon A, Asli B, Braun-Falco M, et al. Schnitzler’s syndrome: diagnosis, treatment, and follow-up. Allergy. 2013;68:562–8.

    Article  CAS  Google Scholar 

  6. Gusdorf L, Asli B, Barbarot S, et al. Schnitzler syndrome: validation and applicability of diagnostic criteria in real-life patients. Allergy. 2017;72:177–82.

    Article  CAS  Google Scholar 

  7. de Koning HD. Schnitzler’s syndrome: lessons from 281 cases. Clin Trans Allergy. 2014;4:41.

    Article  Google Scholar 

  8. Sompuram SR, Bastas G, Vani K, Bogen SA. Accurate identification of paraprotein antigen targets by epitope reconstruction. Blood. 2008;111:302–8.

    Article  CAS  Google Scholar 

  9. Grass S, Preuss KD, Ahlgrimm M, et al. Association of a dominantly inherited hyperphosphorylated paraprotein target with sporadic and familial multiple myeloma and monoclonal gammopathy of undetermined significance: a case-control study. Lancet Oncol. 2009;10:950–6.

    Article  CAS  Google Scholar 

  10. de Koning HD, Schalkwijk J, Stoffels M, et al. The role of interleukin-1 beta in the pathophysiology of Schnitzler’s syndrome. Arthritis Res Ther. 2015;17:187.

    Article  Google Scholar 

  11. Martinez-Taboada VM, Fontalba A, Blanco R, Fernandez-Luna JL. Successful treatment of refractory Schnitzler syndrome with anakinra: comment on the article by Hawkins et al. Arthritis Rheum. 2005;52:2226–7.

    Article  Google Scholar 

  12. de Koning HD, Bodar EJ, Simon A, van der Hilst JC, Netea MG, van der Meer JW. Beneficial response to anakinra and thalidomide in Schnitzler’s syndrome. Ann Rheum Dis. 2006;65:542–4.

    Article  Google Scholar 

  13. de Koning HD, Schalkwijk J, van der Ven-Jongekrijg J, Stoffels M, van der Meer JW, Simon A. Sustained efficacy of the monoclonal anti-interleukin-1 beta antibody canakinumab in a 9-month trial in Schnitzler’s syndrome. Ann Rheum Dis. 2013;72:1634–8.

    Article  Google Scholar 

  14. Krause K, Tsianakas A, Wagner N, et al. Efficacy and safety of canakinumab in Schnitzler syndrome: a multicenter randomized placebo-controlled study. J Allergy Clin Immunol. 2017;139:1311–20.

    Article  CAS  Google Scholar 

  15. Migliorini P, Del Corso I, Tommasi C, Boraschi D. Free circulating interleukin-18 is increased in Schnitzler syndrome: a new autoinflammatory disease? Eur Cytokine Netw. 2009;20:108–11.

    CAS  PubMed  Google Scholar 

  16. Krause K, Feist E, Fiene M, Kallinich T, Maurer M. Complete remission in 3 of 3 anti-IL-6-treated patients with Schnitzler syndrome. J Allergy Clin Immunol. 2012;129:848–50.

    Article  Google Scholar 

  17. Volz T, Wolbing F, Fischer J, et al. Dermal interleukin-1 expression and effective and long-lasting therapy with interleukin-1 receptor antagonist anakinra in Schnitzler syndrome. Acta Derm Venereol. 2012;92:393–4.

    Article  CAS  Google Scholar 

  18. de Koning HD, van Vlijmen-Willems IM, Rodijk-Olthuis D, et al. Mast-cell interleukin-1beta, neutrophil interleukin-17 and epidermal antimicrobial proteins in the neutrophilic urticarial dermatosis in Schnitzler’s syndrome. Br J Dermatol. 2015;173:448–56.

    Article  Google Scholar 

  19. Bonnekoh H, Scheffel J, Maurer M, Krause K. The use of skin biomarker profiles to distinguish Schnitzler’s syndrome from chronic spontaneous urticaria: results of a pilot study. Br J Dermatol. 2018;178(2):561–2.

    Article  CAS  Google Scholar 

  20. Szturz P, Sediva A, Zurek M, et al. Anakinra treatment in Schnitzler syndrome—results of the first retrospective multicenter study in six patients from the Czech Republic. Klin Onkol. 2014;27:111–26.

    Article  CAS  Google Scholar 

  21. Loock J, Lamprecht P, Timmann C, Mrowietz U, Csernok E, Gross WL. Genetic predisposition (NLRP3 V198M mutation) for IL-1-mediated inflammation in a patient with Schnitzler syndrome. J Allergy Clin Immunol. 2010;125:500–2.

    Article  CAS  Google Scholar 

  22. Rowczenio DM, Trojer H, Russell T, et al. Clinical characteristics in subjects with NLRP3 V198M diagnosed at a single UK center and a review of the literature. Arthritis Res Ther. 2013;15:R30.

    Article  Google Scholar 

  23. de Koning HD, van Gijn ME, Stoffels M, et al. Myeloid lineage-restricted somatic mosaicism of NLRP3 mutations in patients with variant Schnitzler syndrome. J Allergy Clin Immunol. 2015;135:561–4.

    Article  Google Scholar 

  24. Krause K, Grattan CE, Bindslev-Jensen C, et al. How not to miss autoinflammatory diseases masquerading as urticaria. Allergy. 2012;67:1465–74.

    Article  CAS  Google Scholar 

  25. Lebbe C, Rybojad M, Klein F, et al. Schnitzler’s syndrome associated with sensorimotor neuropathy. J Am Acad Dermatol. 1994;30(2 Pt 2):316–8.

    Article  CAS  Google Scholar 

  26. Klein CJ, Moon JS, Mauermann ML, et al. The neuropathies of Waldenstrom’s macroglobulinemia (WM) and IgM-MGUS. Can J Neurol Sci. 2011;38:289–95.

    Article  Google Scholar 

  27. Kieffer C, Cribier B, Lipsker D. Neutrophilic urticarial dermatosis: a variant of neutrophilic urticaria strongly associated with systemic disease. Report of 9 new cases and review of the literature. Medicine (Baltimore). 2009;88:23–31.

    Article  Google Scholar 

  28. Niederhauser BD, Dingli D, Kyle RA, Ringler MD. Imaging findings in 22 cases of Schnitzler syndrome: characteristic para-articular osteosclerosis, and the “hot knees” sign differential diagnosis. Skelet Radiol. 2014;43:905–15.

    Article  Google Scholar 

  29. Lipsker D, Veran Y, Grunenberger F, Cribier B, Heid E, Grosshans E. The Schnitzler syndrome. Four new cases and review of the literature. Medicine (Baltimore). 2001;80:37–44.

    Article  CAS  Google Scholar 

  30. Krause K, Weller K, Stefaniak R, et al. Efficacy and safety of the interleukin-1 antagonist rilonacept in Schnitzler syndrome: an open-label study. Allergy. 2012;67:943–50.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Editor information

Editors and Affiliations

Rights and permissions

Reprints and permissions

Copyright information

© 2019 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

de Koning, H.D., Krause, K. (2019). Schnitzler Syndrome. In: Hashkes, P., Laxer, R., Simon, A. (eds) Textbook of Autoinflammation. Springer, Cham. https://doi.org/10.1007/978-3-319-98605-0_37

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-98605-0_37

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-98604-3

  • Online ISBN: 978-3-319-98605-0

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics